Form 4: Eli Lilly EVP & CFO Anat Ashkenazi Reports Stock Transactions

Anat Ashkenazi, EVP & CFO of Eli Lilly, reported acquiring 4,210 shares of common stock and 4,904 restricted stock units, while also disposing of 42,330 shares held indirectly through a 401(k).

Summary

• Anat Ashkenazi, the Executive Vice President and Chief Financial Officer of Eli Lilly & Co, has reported several transactions involving the company's stock.
• On February 12, 2024, Ms. Ashkenazi acquired 4,210 shares of Eli Lilly common stock at a price of $737.26 per share.
• She also acquired 4,904 restricted stock units, each representing a contingent right to receive one share of Eli Lilly common stock, which are exercisable on February 1, 2025.
• Additionally, Ms. Ashkenazi disposed of 42,330 shares of common stock held indirectly through a 401(k) plan.
• Following these transactions, Ms. Ashkenazi directly owns 4,904 restricted stock units and indirectly owns 190 shares through a 401(k).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and restricted stock units by the CFO suggests confidence, while the disposal of shares through a 401(k) is a routine transaction.

Positives

• The acquisition of 4,210 shares by the CFO could be seen as a positive signal of confidence in the company's future performance.
• The acquisition of 4,904 restricted stock units indicates a long-term commitment by the CFO to the company.

Negatives

• The disposal of 42,330 shares through a 401(k) could be interpreted as a slight negative, although it is a common transaction for executives.

Risks

• The sale of a large number of shares, even through a 401(k), could potentially create some short-term selling pressure on the stock.
• Changes in executive holdings can sometimes be interpreted negatively by the market, although this is a routine transaction.

Future Outlook

The restricted stock units will become exercisable on February 1, 2025, which could lead to further transactions at that time.

Management Comments

• The transactions were reported by Jonathan Groff on behalf of Anat Ashkenazi, pursuant to authorization on file.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies and are closely monitored by investors for insights into management's confidence in the company's prospects. This filing is a routine disclosure required by the SEC.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and the transactions reported by Anat Ashkenazi are typical for executives.
• Other pharmaceutical companies such as Pfizer (PFE) and Merck (MRK) also have similar filings when their executives trade company stock.
• The volume of shares traded is not unusual for an executive at a company of Eli Lilly's size.

Stakeholder Impact

• Shareholders may view the CFO's stock acquisitions as a positive sign of confidence in the company's future.
• The transactions are unlikely to have a significant impact on employees, customers, or suppliers.

Next Steps

• The restricted stock units will vest on February 1, 2025, which may result in further transactions.
• Investors will continue to monitor insider transactions for further insights into management's view of the company.

Key Dates

Keywords

insider trading, stock transaction, restricted stock units, executive compensation, Form 4, Eli Lilly, LLY, Anat Ashkenazi